1. Home
  2. AIM

as 05-22-2024 3:32pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

Founded: 1966 Country:
United States
United States
Employees: N/A City: OCALA
Market Cap: 20.5M IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 233.5K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.64 EPS Growth: N/A
52 Week Low/High: $0.32 - $0.75 Next Earning Date: 05-16-2024
Revenue: $193,000 Revenue Growth: 23.72%
Revenue Growth (this year): -30% Revenue Growth (next year): 1735.93%

Share on Social Networks:

Stock Insider Trading Activity of AIM ImmunoTech Inc. (AIM)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Rodino Peter W III AIM COO, Secretary, Gen. Counsel May 6 '24 Buy $0.41 30,865 $12,500.33 212,583 SEC Form 4
Equels Thomas K AIM CEO & President May 6 '24 Buy $0.41 61,729 $25,000.25 778,184 SEC Form 4
BRYAN NANCY AIM Director Mar 21 '24 Buy $0.39 38,462 $15,000.18 38,462 SEC Form 4
Rodino Peter W III AIM COO, Secretary, Gen. Counsel Mar 15 '24 Buy $0.33 37,879 $12,500.07 181,718 SEC Form 4
Equels Thomas K AIM CEO & President Mar 15 '24 Buy $0.33 75,758 $25,000.14 716,455 SEC Form 4